Prescription stimulants are administered to treat disorders in which activity levels, attention, and moods are affected, which is most significantly in conditions of ADHD (Attention deficit hyperactivity disorder). The major use of prescription stimulants is to increase the activity of the CNS (Central Nervous System), majorly by acting on the neurotransmitters norepinephrine and dopamine. Illegal usage of prescription stimulants often stems because of the willingness to cognitive enhancements and is popular in business and academic professionals, majorly athletes, students and performers. According to the various surveys conducted over ten years, prescription stimulants abuse has been consistently on the rise, for instance, approximately 7 million Americans reported the non-medical use of prescription stimulants in 2009. This statistics exceeds the use of cocaine, heroin, hallucinogens, and inhalants combined.
Increasing awareness on prescription stimulants for the treatment of various mental disorders like attention deficit hyperactivity disorders etc. is expected to boost demand for prescription stimulants over the forecast period. Increasing incidence of various disorders like narcolepsy, depression, ADHD, and various acquired brain injuries is also expected to fuel demand for prescription stimulants over the forecast period. Growing popularity of prescription stimulants and increasing funding for researches based on the safe use of these prescription stimulants is also projected to propel market demand for prescription stimulants. However, drug abuse related to prescription stimulants might hinder market growth over the forecast period. The potential for prescription stimulants abuse is increasing owing it to the exponential increase in the availability of these drugs. Also, while prescription stimulants boost mental performance and concentration, it is also linked to causing adverse physiological reactions in the body. Constant abuse can lead to poor health over time. This is anticipated to obstruct market growth for prescription stimulants over the forecast period.
Some of the market participants in the Global Prescription Stimulants market identified across the value chain include: Novartis AG, Janssen Pharmaceuticals, Inc., Hisamitsu Pharmaceutical Co., Inc., Teva Pharmaceutical Industries Ltd., Independence Pharmaceuticals, Arbor Pharmaceuticals Inc., Sun Pharmaceutical Industries Ltd., UCB, Inc., Tris Pharma, Inc., Pfizer Inc., Takeda Pharmaceutical Company Limited, NEOS Therapeutics, Inc., Purdue Pharma L.P., Eli Lilly and Company, and H. Lundbeck A/S.
The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain. The report provides in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.
The report covers exhaustive analysis on:
- Market Segments
- Market Dynamics
- Market Size
- Supply & Demand
- Current Trends/Issues/Challenges
- Competition & Companies involved
- Value Chain
Regional analysis includes
- North America (U.S., Canada)
- Latin America (Argentina, Mexico, Brazil)
- Europe (Germany, Italy, U.K, Spain, France, Russia, Poland)
- Asia Pacific Excluding Japan (India, Australia & New Zealand, China, ASEAN)
- Middle East and Africa (GCC, South Africa, Rest Of MEA)
Avail customized purchase options for your needs
- Detailed overview of parent market
- Changing market dynamics in the industry
- In-depth market segmentation
- Historical, current and projected market size in terms of volume and value
- Recent industry trends and developments
- Competitive landscape
- Strategies of key players and products offered
- Potential and niche segments, geographical regions exhibiting promising growth
- A neutral perspective on market performance
- Must-have information for market players to sustain and enhance their market footprint.
On the basis of Drug Class, Prescription Stimulants Market can be segmented as:
On the basis of Disease Indication, Prescription Stimulants Market can be segmented as:
- Attention-deficit/hyperactivity disorder
- Acquired Brain Injuries
On the basis of Distribution Channel, Prescription Stimulants Market can be segmented as:
- Hospital Pharmacies
- Retail Pharmacies
- Drug Stores
- Mail-order Pharmacies
Global Prescription Stimulants market has witnessed growth due to increasing availability of these drugs for mental care purposes, often abused for mental pleasure. Prescription stimulants come in capsules or tablets. While the abuse, prescription stimulants are injected in liquid form, swallowed, or snorted. Several researches based on prescription stimulants states that the repeated high doses of prescription stimulants over a short period can cause feelings of paranoia and hostility. Prescription stimulants are used to increase levels of dopamine in the brain. Dopamine is a neurotransmitter which is associated with movement, pleasure, and attention. According to a survey conducted by various drug abuse associations, Prescription stimulants such as Ritalin and Adderall are two of the most frequently abused prescription stimulants by high school seniors, with 6.5% reporting non-medical use of Adderall in 2010, in the United States. Prescription stimulants when used legally for treatment of mental disorders, could help patients tremendously. The medical professionals are advised to monitor all possible negative and possible outcomes when they prescribe these stimulants for treatment purposes.
Geographically, global Prescription Stimulants market is segmented into regions viz. North America, Latin America, Asia Pacific and the Middle East & Africa, Western Europe, Eastern Europe. North America’s prescription stimulants market is expanding because of high rate of FDA approved drugs and increasing availability of these prescription stimulants. The market is expected to remain dominant over the period of forecast due to increase in healthcare expenditure and increasing incidence of ADHD, depression and narcolepsy in the region. Europe’s prescription stimulants market is also expected to grow significantly due to high number of manufacturer presence for prescription stimulants and huge teenage population abusing prescription stimulants for mental pleasure. Asia-Pacific prescription stimulants market is anticipated to grow at a decent rate due to growing awareness and availability of prescription stimulants in the region.